Objective: This retrospective hospital based study aimed to describe clinico-radiological features and outcome of neoplastic meningitis (NM) and to evaluate the signifi cance of the presence of malignant cells in CSF and identifi able primary in NM. Methods: The diagnosis of NM was based on the presence of malignant cells in CSF cytology, meningeal biopsy, post mortem examination or compatible clinicoradiological features in patients with known primary malignancy. For subgroup comparisons, Mann Whitney test and Fisher’s exact test were used for continuous and categorical variables respectively. Relative risk of survival in positive CSF cytology for malignant cells and known primary versus negative were calculated. Results: There were 25 patients (mean age 44.5 + 17.6 years) of NM during the study period (2000-2008). They presented with raised ICP headache (72%), cauda equina syndrome (28%), or hemiparesis (12%). Meningeal enhancement and hydrocephalus were seen in 60% and 21% respectively. CSF analysis revealed hypoglychorrachia (64%), raised protein (68%) and pleocytosis (48%). CSF cytology for malignant cells was positive in 76% and cumulative positivity increased by 31% from 1st to 3rd lumbar punctures. A primary could be identifi ed in 56% cases. At last follow up, 16 out of 18 had died. Hypoglychorrachia was the only variable analyzed, which predicted the cytology positivity (p=0.01). The mean duration of survival from the onset was signifi cantly less in cytology positive group (p=0.001). The relative risk of survival at 90 days, 120 and 150 days were signifi cantly higher in cytology and primary negative group compared to positive group. Conclusion: NM with positive cytology or with an identifi able primary tumor has a more aggressive course when compared to the negative groups and former have shorter lifespan. The possibility of positive cytology is high with hypoglychorrachia.

There is a mistake of last two authors' order.

BACKGROUND AND PURPOSE: Thrombolysis >4.5 hours after ischemic stroke onset is unproven. We assessed the feasibility of tenecteplase (TNK) treatment in patients with evidence of an ischemic penumbra 4.5 to 24 hours after onset. METHODS: Acute ischemic stroke patients underwent perfusion computed tomography (CT)/magnetic resonance imaging. Patients with cerebral blood volume (CBV) or diffusion weighted imaging Alberta Stroke Program Early CT Scores (ASPECTS) >6 and mismatch score >2 (defined as >2 ASPECTS regions with delay on mean transit time maps and normal CBV) were eligible for treatment with TNK (0.25 mg/kg). Patients with mismatch patterns enrolled in non-endovascular/non-thrombolysis trials and those without mismatch patterns served as comparators. RESULTS: The median (interquartile range) baseline National Institutes of Health Stroke Scale (NIHSS) in TNK treated patients (n=16) was 12 (range, 8 to 15). In the untreated mismatch (n=18) and nonmismatch (n=23) groups, the baseline NIHSS was 12 (range, 7 to 12) and 16 (range, 8 to 20; P=0.09) respectively. There was one symptomatic hemorrhage each in the TNK group (parenchymal hematoma [PH] 2) and non-mismatch group (PH 2). Penumbral salvage volumes were higher in TNK treated patients (48.3 mL [range, 24.9 to 80.4]) than the non-mismatch (–90.8 mL [range, –197 to –20]; P < 0.0001) patients. CONCLUSIONS: This prospective, non-randomized study supports the feasibility of TNK therapy in patients with evidence of ischemic penumbra 4 to 24 hours after onset.
Alberta ; Blood Volume ; Diffusion ; Hematoma ; Hemorrhage ; Humans ; National Institutes of Health (U.S.) ; Perfusion ; Prospective Studies ; Stroke